FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946882008> ?p ?o ?g. }

• W2946882008 abstract "e21042 Background: Immunotherapy (IT) has demonstrated an improved overall survival (OS) in advanced melanoma with 15% complete responses (CR) in treatment-naïve patients (pts) with brain metastases (met) in the anti-PD1/anti-CTLA4 combination. However, data on brain-met pts who discontinue treatment (EoT) after achieving a CR are lacking. Methods: Disease characteristics and clinical outcome were retrospectively collected from 6 centers on advanced melanoma pts treated with anti-PD1 or anti-PD1/anti-CTLA4. Pts were followed for at least 10 weeks (10.8 – 242). Off-treatment survival (OTS) was defined as time between last IT dose to disease progression or death. Results: Out of 890 pts, 62 achieved a CR; 40 pts stopped treatment due to CR, while 22 due to an adverse event (AE) (n = 19) or investigator decision (n = 3) with subsequent CR. 14 were treated with anti-PD1/anti-CTLA4 and 48 with anti-PD1. 24 had a BRAF mutation, of which 10 had previously received targeted therapy (TT). The median time to first CR was 31 weeks (6 – 138), median duration of response and OTS was 91.1 and 60.7 (10.6 – 242) weeks respectively. OTS was numerically longer for those pts with EoT after AE (85 weeks, 13-242) versus those with EoT due to CR (60 weeks, 11-130). Median OS was not reached. 6/62 (3%) progressed after EoT; 4 locoregionally while 2 were subsequently treated with IT. All pts were alive at last follow-up. 19 pts had brain mets. 8 were BRAF mutated. 10 were treatment naïve, 6 received previously anti-CTLA4, 1 chemotherapy and only 2 TT. Data on reasons for EoT and responses in brain mets are seen in the table. Conclusions: Early data suggest that OTS is numerically longer in patients with EoT due to AE with subsequent CR. EoT due to sustained CR is a feasible option also in brain mets. EoT due to AE with subsequent CR was a more frequent event in the combination treatment. [Table: see text]" @default.
• W2946882008 created "2019-06-07" @default.
• W2946882008 creator A5008364803 @default.
• W2946882008 creator A5009968141 @default.
• W2946882008 creator A5013521399 @default.
• W2946882008 creator A5025478490 @default.
• W2946882008 creator A5031315234 @default.
• W2946882008 creator A5033515147 @default.
• W2946882008 creator A5033599510 @default.
• W2946882008 creator A5040652983 @default.
• W2946882008 creator A5044736874 @default.
• W2946882008 creator A5050031536 @default.
• W2946882008 creator A5065819179 @default.
• W2946882008 creator A5067776208 @default.
• W2946882008 creator A5068961901 @default.
• W2946882008 creator A5082278497 @default.
• W2946882008 creator A5089297467 @default.
• W2946882008 date "2019-05-20" @default.
• W2946882008 modified "2023-10-17" @default.
• W2946882008 title "Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR." @default.
• W2946882008 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e21042" @default.
• W2946882008 hasPublicationYear "2019" @default.
• W2946882008 type Work @default.
• W2946882008 sameAs 2946882008 @default.
• W2946882008 citedByCount "0" @default.
• W2946882008 crossrefType "journal-article" @default.
• W2946882008 hasAuthorship W2946882008A5008364803 @default.
• W2946882008 hasAuthorship W2946882008A5009968141 @default.
• W2946882008 hasAuthorship W2946882008A5013521399 @default.
• W2946882008 hasAuthorship W2946882008A5025478490 @default.
• W2946882008 hasAuthorship W2946882008A5031315234 @default.
• W2946882008 hasAuthorship W2946882008A5033515147 @default.
• W2946882008 hasAuthorship W2946882008A5033599510 @default.
• W2946882008 hasAuthorship W2946882008A5040652983 @default.
• W2946882008 hasAuthorship W2946882008A5044736874 @default.
• W2946882008 hasAuthorship W2946882008A5050031536 @default.
• W2946882008 hasAuthorship W2946882008A5065819179 @default.
• W2946882008 hasAuthorship W2946882008A5067776208 @default.
• W2946882008 hasAuthorship W2946882008A5068961901 @default.
• W2946882008 hasAuthorship W2946882008A5082278497 @default.
• W2946882008 hasAuthorship W2946882008A5089297467 @default.
• W2946882008 hasConcept C121608353 @default.
• W2946882008 hasConcept C126322002 @default.
• W2946882008 hasConcept C143998085 @default.
• W2946882008 hasConcept C2777658100 @default.
• W2946882008 hasConcept C2777701055 @default.
• W2946882008 hasConcept C2778164965 @default.
• W2946882008 hasConcept C2779013556 @default.
• W2946882008 hasConcept C2994587330 @default.
• W2946882008 hasConcept C502942594 @default.
• W2946882008 hasConcept C71924100 @default.
• W2946882008 hasConceptScore W2946882008C121608353 @default.
• W2946882008 hasConceptScore W2946882008C126322002 @default.
• W2946882008 hasConceptScore W2946882008C143998085 @default.
• W2946882008 hasConceptScore W2946882008C2777658100 @default.
• W2946882008 hasConceptScore W2946882008C2777701055 @default.
• W2946882008 hasConceptScore W2946882008C2778164965 @default.
• W2946882008 hasConceptScore W2946882008C2779013556 @default.
• W2946882008 hasConceptScore W2946882008C2994587330 @default.
• W2946882008 hasConceptScore W2946882008C502942594 @default.
• W2946882008 hasConceptScore W2946882008C71924100 @default.
• W2946882008 hasLocation W29468820081 @default.
• W2946882008 hasOpenAccess W2946882008 @default.
• W2946882008 hasPrimaryLocation W29468820081 @default.
• W2946882008 isParatext "false" @default.
• W2946882008 isRetracted "false" @default.
• W2946882008 magId "2946882008" @default.
• W2946882008 workType "article" @default.